SCHEMBL3015734

SCHEMBL3015734

COc1cc(-c2csc(N3CCC(S(=O)(=O)c4ccc(F)cc4)CC3)n2)cc(OC)c1OC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 5/20 0.56
ALDH1A1 P00352 4/20 0.56
GAA P10253 1/20 0.56
MAPT P10636 8/20 0.52
RECQL P46063 2/20 0.52
USP2 O75604 1/20 0.52
HSD17B10 Q99714 1/20 0.52
SMN1; SMN2 Q16637 9/20 0.50
L3MBTL1 Q9Y468 5/20 0.50
AR P10275 3/20 0.48
RAB9A P51151 5/20 0.47
NPC1 O15118 4/20 0.47
LMNA P02545 3/20 0.46
TDP1 Q9NUW8 2/20 0.46
MEN1 O00255 1/20 0.46
POLB P06746 1/20 0.46
KMT2A Q03164 1/20 0.46
HTT P42858 2/20 0.43
TP53 P04637 1/20 0.42
CYP1A2 P05177 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3012579 0.91 ALDH1A1 (0.57) MAPK1ALDH1A1GAAMAPTRECQL
SCHEMBL3013931 0.91 ALDH1A1 (0.57) MAPK1ALDH1A1GAAMAPTRECQL
SCHEMBL3012594 0.91 MAPK1 (0.56) MAPK1ALDH1A1GAAMAPTRECQL
SCHEMBL3011405 0.91 SMN1; SMN2 (0.58) MAPK1ALDH1A1MAPTRECQLUSP2
SCHEMBL3008345 0.91 MAPK1 (0.56) MAPK1ALDH1A1GAAMAPTRECQL
SCHEMBL3016190 0.90 ALDH1A1 (0.53) MAPK1ALDH1A1GAAMAPTRECQL
SCHEMBL2999759 0.90 MAPK1 (0.57) MAPK1ALDH1A1GAAMAPTRECQL
SCHEMBL3006829 0.89 ALDH1A1 (0.54) MAPK1ALDH1A1GAAMAPTRECQL
SCHEMBL3016011 0.89 MAPT (0.61) MAPK1ALDH1A1MAPTRECQLUSP2
SCHEMBL3020987 0.88 ALDH1A1 (0.52) MAPK1ALDH1A1GAAMAPTRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPK1 2767/4885ALDH1A1 3510/4885GAA 110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.